TREATMENT OF ATRIAL FIBRILLATION

That this House is deeply concerned that clinical commissioning groups and GPs across the country are failing to prescribe new oral anti-coagulants (NOACs), which are new life-saving drugs which prevent atrial fibrillation-related strokes; notes that these drugs have been approved by the National Institute for Health and Care Excellence; considers that the short-term cost of these drugs (Apixaban, Dabigatran and Rivaroxaban) is far outweighed by the cost of an atrial fibrillation-related stroke and other preventable illnesses; and recognises that the one million people with atrial fibrillation stand to benefit from NOACs wider use.